The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus
This Italian Delphi underscores the importance of early, personalized HE-DMT use to optimize long-term outcomes in MS. The strong expert alignment reflects a paradigm shift toward proactive treatment and highlights actionable clinical, radiological, and biological indicators that should guide therapeutic decisions. These findings may support national policy changes and promote more equitable and evidence-based access to HE-DMTs across healthcare systems.
Authors
- Diego Centonze (ORCID: https://orcid.org/0000-0002-8390-8545)
- Massimo Filippi (ORCID: https://orcid.org/0000-0002-5485-0479)
- María Trojano (ORCID: https://orcid.org/0000-0002-6329-8946)
- Claudio Gasperini (ORCID: https://orcid.org/0000-0002-3959-4067)
- Matilde Inglese (ORCID: https://orcid.org/0000-0002-9610-0297)
- Paolo Gallo (ORCID: https://orcid.org/0000-0003-3886-4181)
- Francesco Patti (ORCID: https://orcid.org/0000-0002-6923-0846)
- Carlo Pozzilli (ORCID: https://orcid.org/0000-0002-6360-4798)
- Paolo Preziosa (ORCID: https://orcid.org/0000-0002-7826-0019)
- Maria Pia Amato
Institutions
- University of Rome Tor Vergata (IT)
- University of Padua (IT)
- Vita-Salute San Raffaele University (IT)
- San Raffaele University of Rome (IT)
- Istituto Neurologico Mediterraneo (IT)
- University of Catania (IT)
- Don Carlo Gnocchi Foundation (IT)
- Policlinico Universitario di Catania (IT)
- IRCCS Ospedale San Raffaele (IT)
- Ospedale Policlinico San Martino (IT)
- Azienda Ospedale - Università Padova (IT)
- Carlo Forlanini Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University of Florence (IT)
- University of Bari Aldo Moro (IT)
- University of Genoa (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-08-10
- DOI
- https://doi.org/10.1007/s00415-025-13293-9
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- National Multiple Sclerosis Society
- Bristol-Myers Squibb
- Eli Lilly and Company
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Fondazione Italiana Sclerosi Multipla
- Merck KGaA
- GW Pharmaceuticals
- Mylan
- Ministero della Salute
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Novo Nordisk
- National Institutes of Health
- Sanofi Genzyme